Section of Investigative Medicine, Imperial College London, Hammersmith Hospital Campus, London, UK.
Br J Clin Pharmacol. 2012 Dec;74(6):911-9. doi: 10.1111/j.1365-2125.2012.04278.x.
Obesity is a major worldwide health problem. The treatment options are severely limited. The development of novel anti-obesity drugs is fraught with efficacy and safety issues. Consequently, several investigational anti-obesity drugs have failed to gain marketing approval in recent years. Anorectic gut hormones offer a potentially safe and viable option for the treatment of obesity. The prospective utility of gut hormones has improved drastically in recent years with the development of longer acting analogues. Additionally, specific combinations of gut hormones have been demonstrated to have additive anorectic effects. This article reviews the current stage of anti-obesity drugs in development, focusing on gut hormone-based therapies.
肥胖是一个全球性的主要健康问题。治疗选择受到严重限制。新型抗肥胖药物的开发充满了疗效和安全性问题。因此，近年来，几种研究性抗肥胖药物未能获得市场批准。厌食性肠道激素为肥胖的治疗提供了一种潜在的安全可行的选择。近年来，随着长效类似物的发展，肠道激素的预期应用有了显著改善。此外，已经证明特定组合的肠道激素具有相加的厌食作用。本文综述了目前处于开发阶段的抗肥胖药物，重点是基于肠道激素的治疗方法。
